Lung cancer is a common malignancy among both men and women in the USA. The overall prognosis for this disease remains poor, with 13% survival at 5 years for all stages. However, diagnostic techniques and treatment modalities have improved over the past one to two decades. Moreover, advances in molecular biology and genomics have provided valuable insight into disease susceptibility, which may, in turn, impact tumor recurrence and treatment response. The proposed study, a resubmission in response to PA 98-027 (NCI) takes advantage of a large, well-characterized cohort of lung cancer cases established by the PI in 1992. Detailed information will be collected on a cohort of cases recruited between 1992-1999, and, by the end of the proposed study, each case will have been followed for at least 5 years and as long as 13 years. We will utilize both standard molecular biologic techniques as well as single nucleotide polymorphism (SNP) array hybridization technology to test the following hypotheses: (1) polymorphisms in candidate genes involved in a number of xenobiotic and chemotherapeutic drug metabolism, all cycle, DNA repair and invasion pathways are associated with clinical prognosis in NSCLC patients; (2) gene-exposure (smoking) and gene-gene of these polymorphisms modify clinical prognosis in early- and late-stage NSCLC; and (3) using a genome-wide loss of heterozygosity (LOH) map with SNP array hybridization, global tumor LOH is associated with poor prognosis. The proposed studies take advantage of a well-established and well-characterized cohort, an associated extensive tumor bank, and the latest advances in molecular genetics for the study of lung cancer survivorship.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA092824-03
Application #
6793246
Study Section
Epidemiology and Disease Control Subcommittee 2 (EDC)
Program Officer
Arena, Jose Fernando
Project Start
2002-09-20
Project End
2007-08-31
Budget Start
2004-09-01
Budget End
2005-08-31
Support Year
3
Fiscal Year
2004
Total Cost
$568,236
Indirect Cost
Name
Harvard University
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02115
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
Duan, Weiwei; Zhang, Ruyang; Zhao, Yang et al. (2018) Bayesian variable selection for parametric survival model with applications to cancer omics data. Hum Genomics 12:49
Guo, Yichen; Zhang, Ruyang; Shen, Sipeng et al. (2018) DNA Methylation of LRRC3B: A Biomarker for Survival of Early-Stage Non-Small Cell Lung Cancer Patients. Cancer Epidemiol Biomarkers Prev 27:1527-1535
Wang, Zhaoxi; Wei, Yongyue; Zhang, Ruyang et al. (2018) Multi-Omics Analysis Reveals a HIF Network and Hub Gene EPAS1 Associated with Lung Adenocarcinoma. EBioMedicine 32:93-101
Ferreiro-Iglesias, Aida; Lesseur, Corina; McKay, James et al. (2018) Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. Nat Commun 9:3927
Qian, Danwen; Liu, Hongliang; Wang, Xiaomeng et al. (2018) Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival. Int J Cancer :
Shen, Sipeng; Zhang, Ruyang; Guo, Yichen et al. (2018) A multi-omic study reveals BTG2 as a reliable prognostic marker for early-stage non-small cell lung cancer. Mol Oncol 12:913-924
Yin, Jieyun; Liu, Hongliang; Liu, Zhensheng et al. (2017) Pathway-analysis of published genome-wide association studies of lung cancer: A potential role for the CYP4F3 locus. Mol Carcinog 56:1663-1672
Fehringer, Gordon; Brenner, Darren R; Zhang, Zuo-Feng et al. (2017) Alcohol and lung cancer risk among never smokers: A pooled analysis from the international lung cancer consortium and the SYNERGY study. Int J Cancer 140:1976-1984

Showing the most recent 10 out of 108 publications